Dollar Tree shares rose ahead of Tuesday’s opening bell after the discount retailer reiterated its third-quarter outlook and said its CEO was stepping down. Monitor these key chart levels.

Volaris' stock is up 11% since July, driven by cost control and nearshoring trends. See why VLRS stock is a buy with an ...

Luminar is guiding for moderate sequential quarterly sales growth in Q4. Meanwhile, the company's loss is expected to be significantly lower than Q3's, thanks to cost-saving initiatives and a ...

[Photos: PNG/Adobe Stock, vvoe/Adobe Stock, Kyle Grillot/Bloomberg via Getty Images] BY Michael Grothaus 2 minute read Shares in Telsa (NASDAQ: TSLA) are surging this morning after the company ...

The outcome of the presidential election in November should have little impact on the direction of stock prices, Bank of America said. In a note on Friday, Savita Subramanian, a Bank of America ...

You have plenty of company. According to a recent study, when stock prices fall, the number of antidepressant prescriptions rises. The researchers examined the connection by first creating local ...

At the time, Lucid looked poised to fill a gap in the market. Like Tesla, it was a fresh, pure-play EV brand without much ...

The relative strength index indicates bullish price momentum and gives a reading below overbought levels, suggesting the stock has ample room to test higher prices. A bars pattern, which extracts ...

Morgan Stanley shares jumped 6.5% to post a record close, while First Horizon stock price rose 4.1% and US Bancorp rallied 4.7%. Apple stock price fell 0.9%, while Alphabet, Meta Platforms ...

By Matthew Goldstein The stock price of former President Donald J. Trump’s social media company has swung up and down over the past few weeks, but it may be in for an even wilder ride.

NEW YORK, Nov 4 (Reuters) - U.S. companies with lagging stock prices are now quicker to blame management and fire their top executive, but the process of finding a replacement has remained largely ...

H.C. Wainwright raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $27 and keeps a Buy rating on the shares. The ...